86-21-69018966

cpd-service@caerulumpharma.com

Home
About Us
Products
Solutions
Resources
- Downloadable
- Image gallery
FAQs
Contact Us

Home
Products
Featured Products

Products Categories

Antineoplastic
- ACC
- Adenosine A2A
- ALK
- Androgen receptor inhibitor
- Apoptosis stimulant
- ATR
- AXL
- BCl2-BH4
- Bcr-Abl
- BRAF
- BTK
- CDK
- Chk1
- CYP17
- DNA alkylating agent
- EED
- EGFR
- EP4
- ER
- FAK
- FGFR
- FLT3
- Glutaminase
- IDO
- IRA
- KIT
- LXR
- MDM2
- MEK
- MET
- Nrf2
- P90RSK
- P97
- PAKS
- PARP
- PI3K
- Plk-1
- SMYD2
- SRC
- TOPK
- VEGFR
Hypoglycemic drugs
Others
- 5HT
- AMPK
- Arginase
- CRF-1
- CXCR2
- FLAP
- FXR
- GABA
- Gi activator
- GR
- JAK
- LABA
- mAChRs
- NF-κB
- NRTI
- PPAR
- RIP1
- S1PR
- SGC
- SYK
- α2δ-1
- αIIbβ3
- β2-adrenoceptor
- σ1

Featured Products

BAY-293
CPD2809
Factory Directly supply 2019 Amazon Hot Sell Di...
AZD7507
GDC-0077
BI1744-HCl
BLU-667
Mirogabalin besylate
ABBV-744
BMS-986195
PZM-21
AZD-7594
ARS-1620
ARS-1323
ARS-1630
Derazantinib; ARQ-087
BGB-324; Bemcentinib; R428
Ciforadenant; CPI-444; V81444
E-7046
ND-630
ND-646
BLU-554
Bardoxolone methyl
IPI-549

1 2 3 4 Next > >> Page 1 / 4

Contact Us

No. 401, 4th Floor, Building 6, Quwu Road 589, Minhang District, 200241 Shanghai, China
86-21-69018966
Within China:
sales-cpd@caerulumpharma.com
International:
cpd-service@caerulumpharma.com

Inquiry

For inquiries about our products, please leave your email with us and we will be in touch within 24 hours.Inquiry

Latest News

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...
ARS-1620: A promising new inhibitor for K...

According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...
AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

© Copyright - 2015-2022 : All Rights Reserved.

FAQs
Downloadable
Contact Us

QR Code

WhatsApp Online Chat !